乳腺癌患者化疗辅以粒细胞集落刺激因子治疗在MRI上引起的骨髓强化
这项回顾性研究纳入109例接受新辅助化疗辅以G-CSF的乳腺癌患者,测量胸骨骨髓在T1加权增强减影图像上的信号强度指数。骨髓信号强度指数从治疗前2.15显著升至治疗后3.33(p < .001),1年随访时降至1.45(p < .001);50岁以下女性治疗后骨髓强化显著增加,50岁及以上者差异无统计学意义。作者结论认为G-CSF辅以化疗可因骨髓再转化导致胸骨骨髓强化增加,放射科医生应认识此效应以避免误判为骨髓转移。
要点
- 乳腺癌患者化疗辅以G-CSF后胸骨骨髓信号强度指数可由2.15升至3.33,1年随访降至1.45。
- 50岁以下女性G-CSF治疗后骨髓强化显著增加,50岁及以上者差异无统计学意义。
- 阅片时需认识G-CSF所致骨髓再转化的强化表现,避免误判为骨髓转移。
核心结论
- G-CSF辅以化疗可因骨髓再转化导致胸骨骨髓强化增加,放射科医生应认识此效应以避免误判为骨髓转移。
研究设计与样本
- 回顾性研究,纳入109例接受新辅助化疗辅以G-CSF的乳腺癌患者,数据收集于2012年至2017年,随访至2022年8月。
关键影像表现/征象
- 在T1加权增强减影图像上测量胸骨骨髓信号强度,计算骨髓信号强度指数(胸骨骨髓信号强度除以胸壁肌肉信号强度)。
- 骨髓信号强度指数在治疗前为2.15,治疗结束时为3.33,1年随访时为1.45。
诊断标准与关键数值
- 重复测量方差分析显示三个时间点骨髓信号强度指数均值差异显著(F[1.62, 100.67] = 44.57,p < .001)。
- Bonferroni校正事后两两比较:治疗前2.15 vs 治疗后3.33,p < .001;治疗后3.33 vs 1年随访1.45,p < .001。
- 亚组分析:50岁以下女性G-CSF治疗后骨髓强化显著增加;50岁及以上女性差异无统计学意义。
临床应用与阅片要点
- 作者结论认为放射科医生应认识G-CSF辅以化疗所致胸骨骨髓强化增加,以避免误判为骨髓转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Granulocyte-colony stimulating factor (G-CSF) induces the reconversion of fatty bone marrow to hematopoietic bone marrow. The bone marrow changes are detectable as signal intensity changes at MRI. The aim of this study was to evaluate sternal bone marrow enhancement following G-CSF and chemotherapy treatment in women with breast cancer.
MATERIALS AND METHODS: This retrospective study included breast cancer patients who received neoadjuvant chemotherapy with adjunct G-CSF. The signal intensity of sternal bone marrow at MRI on T1-weighted contrast-enhanced subtracted images was measured before treatment, at the end of treatment, and at 1-year follow-up. The bone marrow signal intensity (BM SI) index was calculated by dividing the signal intensity of sternal marrow by the signal intensity of the chest wall muscle. Data were collected between 2012 and 2017, with follow-up until August 2022. Mean BM SI indices were compared before and after treatment, and at 1-year follow-up. Differences in bone marrow enhancement between time points were analyzed using a one-way repeated measures ANOVA.
RESULTS: A total of 109 breast cancer patients (mean age 46.1 ± 10.4 years) were included in our study. None of the women had distal metastases at presentation. A repeated-measures ANOVA determined that mean BM SI index scores differed significantly across the three time points (F[1.62, 100.67] = 44.57, p < .001). At post hoc pairwise comparison using the Bonferroni correction BM SI index significantly increased between initial assessment and following treatment (2.15 vs 3.33, p < .001), and significantly decreased at 1-year follow-up (3.33 vs 1.45, p < .001). In a subgroup analysis, while women younger than 50 years had a significant increase in marrow enhancement after G-CSF treatment, in women aged 50 years and older, the difference was not statistically significant.
CONCLUSION: Treatment with G-CSF as an adjunct to chemotherapy can result in increased sternal bone marrow enhancement due to marrow reconversion. Radiologists should be aware of this effect in order to avoid misinterpretation as false marrow metastases.
引用
- Sorin, Bokov, Haisraely, et al. Treatment-Induced Bone Marrow Enhancement at MRI in Breast Cancer Patients Receiving Granulocyte-Colony Stimulating Factor Adjunct to Chemotherapy. Acad Radiol. 2023. PMID: 37277268. doi:10.1016/j.acra.2023.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。